PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients

Table 3 Univariate and multivariate analyses (Cox proportional hazards model) of OS for patients with stage II/III CRC treated with 5-FU-based chemotherapy according to PIK3CA and/or TP53 mutation status n (%)

	Alive	Dead	Univariate HR (95%CI)	P value	Multivariate HR (95%CI)	P value
PIK3CA
Wild-type	114 (73.08)	42 (26.92)	1 (Ref.)		1 (Ref.)
Occasional	5 (55.56)	4 (44.44)	1.93 (0.69-5.39)	0.208	1.40 (0.49-4.05)	0.530
Recurrent	48 (63.16)	28 (36.84)	1.50 (0.93-2.42)	0.096	1.29 (0.79-2.11)	0.314
TP53
Wild-type	63 (74.12)	22 (25.88)	1 (Ref.)		1 (Ref.)
Occasional	32 (80.00)	8 (20.00)	0.80 (0.35-1.79)	0.583	0.84 (0.37-1.94)	0.687
Recurrent	72 (62.07)	44 (37.93)	1.65 (0.99-2.76)	0.055	1.68 (0.98-2.87)	0.057
PIK3CA and TP53
Both PIK3CA and TP53 Wild-type	49 (76.56)	15 (23.44)	1 (Ref.)		1 (Ref.)
Both PIK3CA and TP53 Mutation	31 (57.41)	23 (42.59)	2.21 (1.15-4.24)	0.017	2.02 (1.04-3.91)	0.037
Others	87 (70.73)	36 (29.27)	1.31 (0.72-2.40)	0.376	1.16 (0.63-2.16)	0.629

Occasional mutation was defined as a single tumor with mutation of PIK3CA or TP53, while recurrent was mutations detected in two or more tumors. HR: Hazard ratio; 95%CI: 95% confidence interval; OS: Overall survival; CRC: Colorectal cancer.